摘要
目的探讨肺腺癌程序性死亡分子-1(programmed death 1,PD-1)、程序性死亡分子配体-1(programmed death ligand 1,PD-L1)蛋白的表达与K-RAS基因突变的相关性。方法采用免疫组化EnVision两步法检测PD-1、PD-L1蛋白的表达,应用实时荧光定量PCR技术检测K-RAS基因的突变类型。结果肺腺癌组织中PD-1、PD-L1的阳性率均高于良性病变肺组织(P<0.01),PD-1、PD-L1蛋白表达与患者性别、年龄、吸烟史、分化程度、淋巴结转移及TNM分期均无相关性(P>0.05)。36例肺腺癌样本中发生K-RAS基因突变者8例(22.2%),K-RAS基因突变与患者性别、年龄、吸烟史、分化程度、淋巴结转移及TNM分期均无关(P>0.05)。相关分析显示PD-1、PD-L1蛋白表达与K-RAS突变无关(P>0.05)。结论 PD-1、PD-L1蛋白在肺腺癌中的表达明显高于良性病变肺组织,但两者表达程度与肺腺癌的临床病理特征及K-RAS基因突变无关。
Purpose To investigate the association of the PD-1 and PD-L1 protein expression with K-RAS gene mutations in lung adenocarcinoma. Methods The protein expression of PD-1 and PD-L1 was detected by immunohistochemical EnVision two-step staining, the K-RAS mutation was examined by real- time fluorescent quantitative PCR. Results The positive rate of PD-1 and PD-L1 was higher in lung adenoearcinoma than benign lung disease （ P 〈 0. 01 ）. There was no relationship between PD-1 and PD-L1 protein expression with the gender, age, smoking condition, differentiation, lymph node metastasis and TNM stages （P 〉0. 05）. The K-RAS gene mutations were detectable in 8 patients （22.2%） among 36 lung adenocarcinoma, there was no association between K-RAS gene mutation with the gender, age, smoking condition, differentiation, lymph node metastasis and TNM stages （P 〉 0. 05）. The eorreetion ana｜ysis showed that there was no relationship between PD-I and PD-L1 protein expression with K-RAS mutation （ P 〉 0. 05 ）. Conclusion The positive rate of PD-I and PD-LI is higher in lung ad- enocarcinoma than benign lung disease, but there is no relation-ship among PD-1 and PD-L1 protein expression with its clinal pathological characteristics and K-RAS mutation in lung adeno-carcinoma.
出处
《临床与实验病理学杂志》
CSCD
北大核心
2017年第7期754-758,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
2016年河北省政府资助临床医学优秀人才培养和基础课题研究(361036)
